/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;}

Thamil Annamalai has 23 years of extensive experience in preclinical research and development within the bio-pharmaceutical industry.  Experience involves pharmacokinetic studies, toxicology studies, and development and validation of pre-clinical models of CNS disorders.  Since joining XenoPort in 2001, she has led in-vivo efforts on a number of discovery programs and is currently Senior Director of in-Vivo Evaluations.  At XenoPort she was involved in submitting several INDs and was part of the NDA submission, with successful approval by FDA.  Prior to joining XenoPort, she was involved in project management in several successful drug discovery and development efforts at IntraBiotics and Microcide Pharmaceuticals for antibacterial and anti fungal programs.  She received her undergraduate degree BSc in Zoology, from University of Madras, India.  She also received her MSc., in Zoology, and MPhil, in Human Physiology from University of Madras, India.